ERBB2 and cancer: Multiple preclinical studies in HER2-positive cells have been performed to understand the molecular mechanism of therapy resistance, but the use of cancer cell lines as the primary model system in those studies does not recapitulate the complexity and heterogeneity of tumorigenesis in organisms.